(Q34280685)

1 August 2017

Clinical application of pharmacogenomics (English)

1 reference

1 August 2017

1 reference

Joseph D Ma

1

1 reference

PubMed ID

22689709

1 August 2017

Kelly C Lee

series ordinal

2

1 reference

PubMed ID

22689709

1 August 2017

Grace M Kuo

series ordinal

3

1 reference

1 August 2017

11 June 2012

1 reference

Journal of Pharmacy Practice

1 August 2017

1 reference

1 August 2017

25

1 reference

1 August 2017

4

1 reference

1 August 2017

417-427

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

1 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

A pharmacogenomics primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenomics: bridging the gap between science and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Drug-drug interaction profiles of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Proton pump inhibitors: an update of their clinical use and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Update on the pharmacogenomics of proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

RNA molecules containing exons originating from different members of the cytochrome P450 2C gene subfamily (CYP2C) in human epidermis and liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Identification and functional characterization of new potentially defective alleles of human CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Increased omeprazole metabolism in carriers of the CYP2C19*17 allele; a pharmacokinetic study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

PM frequencies of major CYPs in Asians and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of sex and menstrual cycle phase on cytochrome P450 2C19 activity with omeprazole used as a biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

CYP2C19 genotype and pharmacokinetics of three proton pump inhibitors in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effects of CYP2C19 gene polymorphism on cure rates for Helicobacter pylori infection by triple therapy with proton pump inhibitor (omeprazole or rabeprazole), amoxycillin and clarithromycin in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

A randomized open trial for comparison of proton pump inhibitors, omeprazole versus rabeprazole, in dual therapy for Helicobacter pylori infection in relation to CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Lafutidine, a novel histamine H2-receptor antagonist, vs lansoprazole in combination with amoxicillin and clarithromycin for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicillin and clarithromycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Impact of clarithromycin resistance and CYP2C19 genetic polymorphism on treatment efficacy of Helicobacter pylori infection with lansoprazole- or rabeprazole-based triple therapy in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Effect of proton pump inhibitors on platelet inhibition activity of clopidogrel in Chinese patients with percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Codeine, ultrarapid-metabolism genotype, and postoperative death

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Ethical considerations in CYP2D6 genotype testing for codeine-prescribed breastfeeding mothers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Did the drug cause death? Codeine and breastfeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Codeine intoxication associated with ultrarapid CYP2D6 metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

AmpliChip CYP450 test: personalized medicine has arrived in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Epidemiology of hypersensitivity drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Concordance of primary generalised epilepsy and carbamazepine hypersensitivity in monozygotic twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenetics of cutaneous adverse drug reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Pharmacogenetics of toxic epidermal necrolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

A marker for Stevens-Johnson syndrome ...: ethnicity matters

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Genetic variants in microsomal epoxide hydrolase influence carbamazepine dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA-B locus in Caucasian patients with carbamazepine hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Medical genetics: a marker for Stevens-Johnson syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

FDA: Epilepsy drugs may carry skin risks for Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA-B*1502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens-Johnson syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Cross-sensitivity of skin rashes with antiepileptic drug use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Cross-reactivity pattern of rash from current aromatic antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Identification and functional characterization of eight CYP3A4 protein variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

Assessment of the pharmacogenomics educational needs of pharmacists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F0897190012448309

21 January 2018

Identifiers

DOI

10.1177/0897190012448309

1 reference

1 August 2017

1 reference

PubMed ID

22689709